Table 1.
Clinical characteristics of study population (n = 28)
| Variable | Value |
|---|---|
| Age (y) | 54 ± 13 |
| Women | 20 (71%) |
| Height (cm) | 165 ± 11 |
| Weight (kg) | 71 ± 18 |
| Body surface area (m2) | 1.8 ± 0.3 |
| Heart rate (beats/min) | 79 ± 13 |
| Mean PASP on RHC (mm Hg) | 47 ± 12 |
| Pulmonary vasodilators | |
| Endothelin antagonists | 11 (39%) |
| PDE5 antagonists | 18 (64%) |
| Oral prostanoid | 1 (4%) |
| Inhaled prostanoid | 1 (4%) |
| RV EDV (mL/m2) | 98 ± 26 |
| RV ESV (mL/m2) | 59 ± 23 |
| RV EF (%) | 41 ± 11 |
EDV, End-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; PASP, pulmonary artery systolic pressure; PDE5, phosphodiesterase 5; RHC, right heart catheterization.
Data are expressed as mean ± SD or as number (percentage). RV volumes are derived from cardiac magnetic resonance imaging.